Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bempegaldesleukin in mild COVID-19
NCT04646044Phase 1Completed
- Sponsor
- Nektar Therapeutics
- Start
- Nov 2020
- Primary completion
- May 2021
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing Bempegaldesleukin + SOC with Placebo + SOC (2 arms). Primary endpoints: AUC of Bempegaldesleukin, Cmax of Bempegaldesleukin and 4 more. Started Nov 2020; status: completed.
02
Drugs
bempegaldesleukin
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04646044.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04646044.